Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Prestwick2_001079

    Client Email Product

    Prestwick2_001079

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Formulations

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    5
    US DMFs Filed

    US DMFs Filed

    1
    CEP/COS Certifications

    CEP/COS Certifications

    1
    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    1
    Other Suppliers

    Other Suppliers

    5
    API REF. PRICE (USD / KG)
    41,937

    API Market Place

    1
    INTERMEDIATES
    1
    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    1
    Europe

    Europe

    5
    Canada

    Canada

    1
    Australia

    Australia

    1
    South Africa

    South Africa

    1
    Uploaded Dossiers

    Uploaded Dossiers

    3
    GLOBAL SALES (USD Million)

    U.S. Medicaid

    53.00

    Annual Reports

    0

    FDF Market Place

    3
    EXCIPIENTS
    122
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    0

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    4

    News

    18
    REF STANDARD

    EDQM

    1

    USP

    1

    JP

    0

    Other Listed Suppliers

    2
    SERVICES
    1
    Full View ScreenFull Screen View
    Venetoclax Plus Obinutuzumab Demonstrates Durable Survival Benefit
    Venetoclax Plus Obinutuzumab Demonstrates Durable Survival Benefit

    https://investor.seagen.com/press-releases/news-details/2023/Phase-3-Trial-of-ADCETRIS-brentuximab-vedotin-with-Modified-Chemo-Regimen-Shows-Non-Inferiority-with-Unprecedented-3-Year-Progression-Free-Survival-of-94.9-vs-Less-Tolerable-International-Standard-of-Care-in-Advanced-Classical-Hodgkin-Lymphoma/default.aspx

    PRESS RELAESE
    22 Jun 2023
    Share Share
    Chugai Pharma’s Gazyva gets Japanese MHLW approval for an additional indication
    Chugai Pharma’s Gazyva gets Japanese MHLW approval for an additional indication

    http://pharmabiz.com/NewsDetails.aspx?aid=155345&sid=2

    PHARMABIZ
    24 Dec 2022
    Share Share
    J&J gets EMA backing for Imbruvica-venetoclax combination
    J&J gets EMA backing for Imbruvica-venetoclax combination

    https://www.fiercepharma.com/pharma/planning-all-oral-once-daily-regimen-jj-gets-ema-backing-imbruvica-venetoclax-combination

    Nick Paul Taylor FIERCEPHARMA
    29 Jun 2022
    Share Share
    TG Therapeutics Falls 30% As CEO Discloses Partial Clinical Hold
    TG Therapeutics Falls 30% As CEO Discloses Partial Clinical Hold

    https://finance.yahoo.com/news/tg-therapeutics-falls-30-ceo-173034141.html

    V. Singh YAHOO FINANCE
    28 Jan 2022
    Share Share
    First-Line Ibrutinib/Venetoclax Better Than Chlorambucil/Obinutuzumab
    First-Line Ibrutinib/Venetoclax Better Than Chlorambucil/Obinutuzumab

    https://www.cancertherapyadvisor.com/home/news/conference-coverage/eha2021-virtual-congress/chronic-leukemia-cll-ibrutinib-venetoclax-therapy-improve-outcome/

    CANCERTHERAPYADVISOR
    18 Jun 2021
    Share Share
    IMBRUVICA Plus VENCLEXTA/VENCLYXTO (venetoclax) Combination Positive Results
    IMBRUVICA Plus VENCLEXTA/VENCLYXTO (venetoclax) Combination Positive Results

    https://news.abbvie.com/news/press-releases/imbruvica-ibrutinib-plus-venclextavenclyxto-venetoclax-combination-shows-superior-progression-free-survival-compared-to-chlorambucil-plus-obinutuzumab-in-first-line-chronic-lymphocytic-leukemia-cll-phase-3-glow-study.htm

    PRESS RELEASE
    14 Jun 2021
    Share Share
    First-Line Ibrutinib + Venetoclax Is Superior to Chlorambucil + Obinutuzumab
    First-Line Ibrutinib + Venetoclax Is Superior to Chlorambucil + Obinutuzumab

    https://www.prnewswire.com/news-releases/european-hematology-association--first-line-ibrutinib--venetoclax-is-superior-to-chlorambucil--obinutuzumab-for-chronic-lymphocytic-leukemiasmall-lymphocyte-lymphoma-301310009.html

    PRNEWSWIRE
    12 Jun 2021
    Share Share
    TG's leukemia combo clears phase 3, aims for 2020 filing
    TG's leukemia combo clears phase 3, aims for 2020 filing

    https://www.fiercebiotech.com/biotech/tg-therapeutics-leukemia-combo-clears-phase-3-aims-for-2020-filing

    Amirah Al Idrus FIERCE BIOTECH
    05 May 2020
    Share Share
    FDA lifts hold on AbbVie, Roche's Venclexta in myeloma
    FDA lifts hold on AbbVie, Roche's Venclexta in myeloma

    https://www.fiercepharma.com/pharma/fda-lifts-partial-hold-venclexta-trial-multiple-myeloma-after-a-spate-deaths

    K. Blankenship Fierce Pharma
    25 Jun 2019
    Share Share
    AstraZeneca's Calquence sets Imbruvica in its sights
    AstraZeneca's Calquence sets Imbruvica in its sights

    https://www.fiercepharma.com/pharma/astrazeneca-s-calquence-sets-imbruvica-its-sights-promising-solo-cll-data

    Kyle Blankenship FIERCE PHARMA
    17 Jun 2019
    Share Share
    AstraZeneca's Calquence treads on Imbruvica's turf with second phase 3 CLL win
    AstraZeneca's Calquence treads on Imbruvica's turf with second phase 3 CLL win

    https://www.fiercepharma.com/pharma/astrazeneca-s-calquence-treads-imbruvica-s-turf-second-ph3-cll-win

    Carly Helfand FIERCE PHARMA
    07 Jun 2019
    Share Share
    AbbVie unveils Venclexta data
    AbbVie unveils Venclexta data

    https://www.fiercepharma.com/pharma/abbvie-unveils-venclexta-data-scored-lightning-fast-cll-combo-nod

    Carly Helfand FIERCE PHARMA
    04 Jun 2019
    Share Share
    Roche announces positive results from Gazyva/Gazyvaro phase 3 study
    Roche announces positive results from Gazyva/Gazyvaro phase 3 study

    http://www.pharmabiz.com/NewsDetails.aspx?aid=99063&sid=2

    PHARMABIZ
    05 Dec 2016
    Share Share
    Italian pharma scandals prompts call for EU-wide pricing probe
    Italian pharma scandals prompts call for EU-wide pricing probe

    http://www.pmlive.com/pharma_news/italian_pharma_scandals_prompts_call_for_eu-wide_pricing_probe_1168682

    Phil Taylor PMLIVE
    19 Oct 2016
    Share Share
    AbbVie, J&J leukemia drug cuts death risk vs chemo in new patients: study
    AbbVie, J&J leukemia drug cuts death risk vs chemo in new patients: study

    http://www.reuters.com/article/us-health-blood-johnson-johnson-idUSKBN0TP0KY20151206#I7Wtc7obcpoRicEo.97

    Bill Berkrot REUTERS
    08 Dec 2015
    Share Share
    AbbVie's Imbruvica, Amgen's Kyprolis shine at annual ASH meeting
    AbbVie's Imbruvica, Amgen's Kyprolis shine at annual ASH meeting

    http://www.fiercepharmamarketing.com/story/abbvies-imbruvica-amgens-kyprolis-shine-annual-ash-meeting/2015-12-07

    Carly Helfand FIERCE PHARMA MARKETING
    07 Dec 2015
    Share Share
    Attix Pharmaceuticals Recalls Hundreds of APIs From the U.S.
    Attix Pharmaceuticals Recalls Hundreds of APIs From the U.S.

    http://www.fiercepharmamanufacturing.com/story/attix-pharmaceuticals-recalls-hundreds-apis-us/2015-04-30

    Eric Palmer FIERCE PHARMA MFG
    02 May 2015
    Share Share
    Novartis' Arzerra Shows Benefit in Relapsed CLL
    Novartis' Arzerra Shows Benefit in Relapsed CLL

    http://www.pharmatimes.com/Article/15-04-27/Novartis_Arzerra_shows_benefit_in_relapsed_CLL.aspx

    Selina Mckee PHARMATIMES
    27 Apr 2015
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search